Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTA vs FINGOLIMOD HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,Reduction of risk of hospitalization and all-cause mortality in COVID-19 (EUA, no longer authorized)
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
0.5 mg orally once daily
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Terminal elimination half-life is approximately 6–9 days; due to extensive tissue distribution, steady-state is reached within 1–2 months of daily dosing.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Primarily metabolized by cytochrome P450 4F2 (CYP4F2) via omega-hydroxylation; also undergoes hydrolysis by non-CYP enzymes. Minor contribution from CYP3A4.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Primarily hepatic metabolism (CYP4F2) with subsequent biliary/fecal elimination (81% of total clearance); renal excretion accounts for <2.5% of unchanged drug.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
>99.7% bound to plasma proteins, primarily albumin and lipoproteins.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Approximately 1700 L (17 ± 6 L/kg) indicating extensive distribution into tissues, including erythrocytes, brain, and adipose tissue.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Oral bioavailability is approximately 93% (range 80–100%).
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No dose adjustment required for GFR ≥15 m L/min. Fingolimod has not been studied in ESRD (GFR <15 m L/min) or dialysis; use caution.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Child-Pugh A or B: No dose adjustment. Child-Pugh C: Contraindicated.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
For patients ≥10 years and >40 kg: 0.5 mg orally once daily. For patients <40 kg or <10 years: Safety and efficacy not established.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
No specific dose adjustment; use caution due to increased risk of bradycardia, infections, and comorbidities.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Increased risk of serious infections, including life-threatening opportunistic infections such as progressive multifocal leukoencephalopathy (PML), cryptococcal meningitis, and herpes virus infections. Baseline and periodic monitoring required.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Risk of bradyarrhythmia and atrioventricular block at treatment initiation; require ECG monitoring. Macular edema, especially in patients with uveitis or diabetes. Reduced pulmonary function; avoid in severe respiratory disease. Posterior reversible encephalopathy syndrome (PRES). Hepatic injury; monitor liver enzymes. Fetal harm; effective contraception required. Increased risk of infections; withhold during serious infection. Avoid live vaccines during and for 2 months after treatment.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Hypersensitivity to fingolimod or any component. Recent (within 6 months) myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure, or NYHA class III/IV heart failure. History of Mobitz type II 2nd-degree or 3rd-degree AV block or sick sinus syndrome unless pacemaker in place. Severe untreated sleep apnea. Baseline prolonged QTc interval (>500 msec) or concurrent Class Ia or Class III antiarrhythmic drugs.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Grapefruit and grapefruit juice increase fingolimod exposure by inhibiting CYP3A4 and CYP4F2; avoid concurrent consumption.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
First trimester: FDA Pregnancy Category C. Animal studies show embryolethality, fetal malformations (including persistent truncus arteriosus and ventricular septal defects) and increased resorptions. In humans, S1P receptor modulators are associated with a 2-fold increase in major congenital malformations when exposed in the first trimester. Second and third trimesters: Risk of fetal bradycardia, QT prolongation, and growth restriction due to maternal lymphopenia and immune modulation.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Unknown if excreted in human breast milk. M/P ratio not established. Due to potential for serious adverse reactions in breastfed infants (e.g., immunosuppression), advise against breastfeeding during therapy and for 2 months after last dose.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
No specific dose adjustments established for pregnancy; however, pharmacokinetic changes (increased volume of distribution, renal clearance) may reduce drug exposure. Fingolimod is contraindicated in pregnancy due to fetal risk; use only if benefit justifies risk. Discontinue at least 2 months before planned conception due to long half-life (6-9 days).
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
First-dose monitoring required for 6 hours post-initial dose due to bradycardia risk; obtain baseline ECG, blood pressure, and heart rate. Avoid use in patients with recent MI, unstable angina, stroke, TIA, or certain arrhythmias. Vaccinate against varicella zoster virus (VZV) before initiation if no history of chickenpox or vaccination. Monitor for macular edema, especially in patients with diabetes or uveitis. Lymphopenia is expected; do not discontinue for low lymphocyte counts unless infection occurs.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
Take exactly as prescribed; do not stop without consulting your doctor.,You will be observed for at least 6 hours after your first dose to monitor heart rate.,Report any signs of infection (fever, cough, painful urination) immediately.,Report any vision changes, such as blurriness or blind spots.,Avoid live vaccines while taking this medication and for 2 months after stopping.,Fingolimod can harm a fetus; use effective contraception during treatment and for 2 months after stopping.,Avoid grapefruit and grapefruit juice as they may increase side effects.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
"Fingolimod, a sphingosine 1-phosphate receptor modulator used for multiple sclerosis, can inhibit the metabolism of lorcaserin, a serotonin 2C receptor agonist for weight management. This occurs via fingolimod's moderate inhibition of CYP2D6, the primary enzyme responsible for lorcaserin's oxidative deamination. Increased lorcaserin exposure may heighten the risk of serotonin-related adverse effects, including nausea, headache, and potentially life-threatening serotonin syndrome."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
"Dexamethasone, a potent corticosteroid with profound immunosuppressive and anti-inflammatory effects, may potentiate the immunosuppressive actions of fingolimod, a sphingosine-1-phosphate receptor modulator used in multiple sclerosis. This additive immunosuppression increases the risk of opportunistic infections, including viral reactivation (e.g., herpes zoster) and serious bacterial infections. Clinical outcomes may range from prolonged infections to life-threatening sepsis, particularly in patients receiving high-dose or prolonged dexamethasone therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTA vs FINGOLIMOD HYDROCHLORIDE, answered by our medical review team.
ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. FINGOLIMOD HYDROCHLORIDE is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTA and FINGOLIMOD HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. The standard adult dose of FINGOLIMOD HYDROCHLORIDE is: 0.5 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTA and FINGOLIMOD HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. FINGOLIMOD HYDROCHLORIDE is classified as Category C. First trimester: FDA Pregnancy Category C. Animal studies show embryolethality, fetal malformations (including persistent truncus arteriosus and ventricular septal defects) and inc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.